You are receiving this email because you are subscribed to Daily Insider Trades. If you no longer wish to receive these emails, please unsubscribe here. |
|
|
Targeting companies with recently announced takeover deals can often lead to low-risk gains.
The potential for profit is even higher if you buy shares of stocks that are receiving takeover interest or are actively exploring a sale. Share prices usually rise after a takeover deal has been announced, and takeover deals are frequently announced at a significant premium above current share prices.
Here are three takeover targets for the week - |
Golden Ocean Group Limited – SYM: GOGL
Recent Price: $7.65
Takeover Action: Golden Ocean and Cmb.Tech signed a term sheet outlining a proposed stock-for-stock merger, with Cmb.Tech as the surviving entity. Under the agreed terms, Golden Ocean shareholders would receive 0.95 shares of Cmb.Tech for each Golden Ocean share held, at about $8.43 per share.
Golden Ocean Group Limited, a shipping company, owns and operates a fleet of dry bulk vessels worldwide. Its dry bulk vessels consist of Newcastlemax, Capesize, Kamsarmax, and Panamax vessels operating in the spot and time charter markets. The company also transports various bulk commodities, including ores, coal, grains, and fertilizers. As of March 20, 2025, it owned a fleet of 83 dry bulk vessels. Golden Ocean Group Limited is based in Hamilton, Bermuda. |
Right now, there's a tiny tech stock with a market cap of just about $150 million...
But not barely three years ago - it was worth about $6 billion...
About 40X where it is today.
And right now, my flagship Stealth Trades system is telling me this stock could be setting up for a mega breakout higher.
If it gets anywhere even close to its 2020 price - you could be in for huge returns...
Because remember, going back to its previous price would mean a 4,000% gain...
Enough to turn a single $1,000 stake into $40,000....
A $2,500 stake into a retirement-boosting $100,000...
And a $10,000 stake into a buy-yourself-a-house $400,000.
If you miss out on this, you may remember this for years to come...
So, don't allow that to happen.
All you have to do to get the details on this potential millionaire-maker tech stock...
Is to click here to get a full year of Stealth Trades for just $5 - before it takes off without you. |
Arcellx, Inc. – SYM: ACLX
Recent Price: $63.79
Takeover Action: Arcellx's preliminary data from its pivotal Phase II trial was so positive that it revived talk about the company being an acquisition target. The company has attracted investments from 37 hedge funds, suggesting a moderate level of institutional engagement.
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California. Click here to continue reading the full article and see our last pick. |
|
|
Our mailing address is:
DC2 Publishing LLC
4260 NW 1st Avenue Suite # 55
Boca Raton, FL 33431 - 4264 Daily Insider Trades
Copyright © 2025 DC2 Publishing LLC, All rights reserved.
You're receiving this email as part of your subscription to Daily Insider Trades. For more information about our privacy practices, please review our Privacy Policy or our Terms of Use.
|
|
|
|
Post a Comment
Post a Comment